Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

J Donnez, HS Taylor, EA Stewart, L Bradley, E Marsh… - The Lancet, 2022 - thelancet.com
Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …
被引用次数：42 相关文章

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

J Donnez, HS Taylor, EA Stewart… - Lancet (London …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

J Donnez, HS Taylor, EA Stewart, L Bradley, E Marsh… - The Lancet, 2022 - Elsevier
Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials

J Donnez, HS Taylor, EA Stewart… - Obstetrical & …, 2022 - journals.lww.com
Uterine fibroids occur in 50% to 60% of women and are symptomatic in 30% of patients by
causing abnormal uterine bleeding and pelvic pressure. Treatment of uterine fibroids …

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

J Donnez, HS Taylor, EA Stewart, L Bradley… - The …, 2022 - mayoclinic.elsevierpure.com
Background: Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.

J Donnez, HS Taylor, EA Stewart, L Bradley… - Lancet (London …, 2022 - europepmc.org
Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials

J Donnez, HS Taylor, EA Stewart… - Obstetrical & …, 2022 - journals.lww.com
Uterine fibroids occur in 50% to 60% of women and are symptomatic in 30% of patients by
causing abnormal uterine bleeding and pelvic pressure. Treatment of uterine fibroids …

[引用][C] Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 …

J Donnez, HS Taylor, EA Stewart… - Obstetrical and …, 2022 - mayoclinic.elsevierpure.com
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic
Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials — Mayo Clinic Skip …